FDA advisers are meeting for two days to review evidence for seven experimental peptide therapies, including TB-500, BPC-157, and MOTs-C, to determine if they can be compounded by specialized pharmacies despite FDA scientists' recommendations against approval due to limited human data.
An FDA panel is set to review seven peptides, popular in wellness circles for injury recovery and more, but lacking large-scale trials and FDA approval. Concerns linger about safety and potential conflicts of interest among panel members.
FDA scientists recommend against loosening restrictions on trendy peptide therapies like BPC-157 and MOTs-C, citing a lack of rigorous human trials and potential safety concerns. This contrasts with Health Secretary Robert F. Kennedy Jr.'s support for the molecules, despite a 2023 ban on compounding pharmacies making them.
